Active and total transforming growth factor-β1 are differentially regulated by dopamine and estradiol in the pituitary

Endocrinology. 2011 Jul;152(7):2722-30. doi: 10.1210/en.2010-1464. Epub 2011 Apr 26.

Abstract

Dopamine, acting through the dopamine type 2 receptor (Drd2), is the main inhibitor of pituitary prolactin (PRL) secretion and lactotroph proliferation. TGF-β1 is involved, at least in part, in mediating these actions. It was described that TGF-β1 synthesis in rat pituitary lactotrophs is up-regulated by dopamine and down-regulated by estradiol. TGF-β1 is secreted as a large latent complex. The local regulation of cytokine activation in the pituitary has not yet been explored. In this work, we studied pituitary active and total TGF-β1 content, as well as TGF-β1 mRNA, and the in vivo role of dopamine and estradiol on pituitary TGF-β1 levels. Adult female mice (wild type), and female mice with a null mutation in the Drd2 (Drd2(-/-)), were used. The loss of dopaminergic tone induced a decrease in TGF-β1 mRNA expression, in active and total cytokine content, and in TGF-β type II receptor expression. Dopamine regulation of pituitary TGF-β1 activation process was inferred by the inhibition of active cytokine by in vivo sulpiride treatment. Interestingly, in the absence of dopaminergic tone, estradiol induced a strong increase in active TGF-β1. PRL secretion correlated with active, but not total cytokine. TGF-β1 inhibitory action on lactotroph proliferation and PRL secretion was decreased in Drd2(-/-) pituitary cells, in correlation with decreased TGF-β type II receptor. The study of the TGF-β1 activation process and its regulation is essential to understand the cytokine activity. As an intermediary of dopamine inhibition of lactotroph function, TGF-β1 and local activators may be important targets in the treatment of dopamine agonist-resistant prolactinomas.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Proliferation
  • Cells, Cultured
  • Dopamine Agonists / pharmacology*
  • Dopamine Agonists / therapeutic use
  • Dopamine Antagonists / pharmacology*
  • Dopamine Antagonists / therapeutic use
  • Dopamine D2 Receptor Antagonists
  • Estradiol / analogs & derivatives*
  • Estradiol / pharmacology
  • Estradiol / therapeutic use
  • Female
  • Gene Expression Regulation / drug effects*
  • Hyperprolactinemia / drug therapy
  • Lactotrophs / drug effects
  • Lactotrophs / metabolism
  • Mice
  • Mice, 129 Strain
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Pituitary Gland, Anterior / cytology
  • Pituitary Gland, Anterior / drug effects*
  • Pituitary Gland, Anterior / metabolism
  • Prolactin / blood
  • Prolactin / metabolism
  • Protein Serine-Threonine Kinases / metabolism
  • RNA, Messenger / metabolism
  • Receptor, Transforming Growth Factor-beta Type II
  • Receptors, Dopamine D2 / agonists
  • Receptors, Dopamine D2 / genetics
  • Receptors, Dopamine D2 / metabolism*
  • Receptors, Transforming Growth Factor beta / metabolism
  • Transforming Growth Factor beta1 / genetics
  • Transforming Growth Factor beta1 / metabolism*

Substances

  • Dopamine Agonists
  • Dopamine Antagonists
  • Dopamine D2 Receptor Antagonists
  • RNA, Messenger
  • Receptors, Dopamine D2
  • Receptors, Transforming Growth Factor beta
  • Tgfb1 protein, mouse
  • Transforming Growth Factor beta1
  • Estradiol
  • Prolactin
  • Protein Serine-Threonine Kinases
  • Receptor, Transforming Growth Factor-beta Type II